Stay updated on Divarasib Combo in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedA new history entry dated 2025-12-24 adds Contacts/Locations and Study Status (with version 37 appearing on 2025-12-22); the entry from 2025-11-28 was removed.SummaryDifference0.3%

- Check17 days agoChange DetectedFooter now lists Revision: v3.3.3; the HHS Vulnerability Disclosure section and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedA new study record for Divarasib in KRAS G12C NSCLC (KRAScendo 170) was added with eligibility, outcome measures, arms and interventions, study design, study description, study status, and study identification. The prior record for Divarasib in combination with other therapies (KRASendo 170) was removed.SummaryDifference0.7%

- Check45 days agoChange DetectedThe page shows an added revision tag v3.3.2 and the previous tag v3.2.0 has been removed.SummaryDifference0.1%

- Check52 days agoChange DetectedA new version dated 2025-11-10 adds a Study Status update to the trial record, following an earlier 2025-11-07 entry. A banner notice about government funding lapses was removed from the page.SummaryDifference0.7%

- Check67 days agoChange DetectedThe new screenshot shows the same Record History content and version list with only minor UI/layout changes; no substantive study details or status changes are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Divarasib Combo in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Divarasib Combo in KRAS G12C NSCLC Clinical Trial page.